MXPA05010707A - Combinaciones que comprenden farmacos anti-epilepticos para el tratamiento de desordenes neurologicos. - Google Patents

Combinaciones que comprenden farmacos anti-epilepticos para el tratamiento de desordenes neurologicos.

Info

Publication number
MXPA05010707A
MXPA05010707A MXPA05010707A MXPA05010707A MXPA05010707A MX PA05010707 A MXPA05010707 A MX PA05010707A MX PA05010707 A MXPA05010707 A MX PA05010707A MX PA05010707 A MXPA05010707 A MX PA05010707A MX PA05010707 A MXPA05010707 A MX PA05010707A
Authority
MX
Mexico
Prior art keywords
combinations
treatment
neurological disorders
epileptic drugs
epileptic
Prior art date
Application number
MXPA05010707A
Other languages
English (en)
Spanish (es)
Inventor
Lingenhohl Kurt
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA05010707A publication Critical patent/MXPA05010707A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
MXPA05010707A 2003-04-04 2004-04-02 Combinaciones que comprenden farmacos anti-epilepticos para el tratamiento de desordenes neurologicos. MXPA05010707A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0307860.7A GB0307860D0 (en) 2003-04-04 2003-04-04 Organic compounds
PCT/EP2004/003518 WO2004087161A1 (en) 2003-04-04 2004-04-02 Combinations comprising anti-epileptic drugs for the treatment of neurological disorders

Publications (1)

Publication Number Publication Date
MXPA05010707A true MXPA05010707A (es) 2005-12-12

Family

ID=9956223

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010707A MXPA05010707A (es) 2003-04-04 2004-04-02 Combinaciones que comprenden farmacos anti-epilepticos para el tratamiento de desordenes neurologicos.

Country Status (10)

Country Link
US (1) US20060194766A1 (cg-RX-API-DMAC7.html)
EP (1) EP1620103A1 (cg-RX-API-DMAC7.html)
JP (1) JP2006522062A (cg-RX-API-DMAC7.html)
CN (1) CN100546581C (cg-RX-API-DMAC7.html)
AU (1) AU2004226825B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0409170A (cg-RX-API-DMAC7.html)
CA (1) CA2521274A1 (cg-RX-API-DMAC7.html)
GB (1) GB0307860D0 (cg-RX-API-DMAC7.html)
MX (1) MXPA05010707A (cg-RX-API-DMAC7.html)
WO (1) WO2004087161A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US20100168174A1 (en) * 2007-07-13 2010-07-01 Eisai R&D Management Co., Ltd. Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain
WO2009015244A1 (en) * 2007-07-23 2009-01-29 Synosia Therapeutics Rufinamide for the treatment of post-traumatic stress disorder
ES2742728T3 (es) 2009-07-22 2020-02-17 PureTech Health LLC Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
PT3856182T (pt) 2018-09-28 2026-03-10 Karuna Therapeutics Inc Composições e métodos para o tratamento de perturbações melhoradas pela ativação dos recetores muscarínicos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB864536A (en) * 1957-11-06 1961-04-06 Sapos S A Lab ª‡-ethyl-phenylacetylurea
GB1028234A (en) * 1964-01-06 1966-05-04 Ici Ltd New pharmaceutical compositions comprising 5-aminodibenzocycloheptene derivatives
WO1989005642A1 (en) * 1987-12-22 1989-06-29 Ferkany John W Dextrorphan potentiator for anticonvulsant composition and method
US5095033A (en) * 1991-03-01 1992-03-10 Laboratoires Biocodex Method for treating epilepsy
IT1261808B (it) * 1993-07-06 1996-06-03 Impiego di l-carnitina o acido l-carnitine e valproato nel trattamentodei disosrdini convulsivi
DE69724144D1 (de) * 1996-10-19 2003-09-18 Univ Wales Bangor Verfahren zur herstellung von chemisch reaktiver stärke
CZ141399A3 (cs) * 1996-10-24 1999-07-14 Novartis Ag Substituované aminoalkanfosfonové kyseliny, způsob jejich přípravy a farmaceutické prostředky, které je obsahují
US6306909B1 (en) * 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
CN1265889A (zh) * 1999-03-06 2000-09-13 王学勇 一种治疗癫痫病的药物
CA2392879C (en) * 1999-12-01 2005-03-29 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
IL161700A0 (en) * 2001-11-12 2004-09-27 Novartis Ag Monohydroxycarbamazepine for use in the preparation of a medicament for the treatment of affective and attention disorder and neuropathic pain

Also Published As

Publication number Publication date
AU2004226825A1 (en) 2004-10-14
CN100546581C (zh) 2009-10-07
BRPI0409170A (pt) 2006-04-11
CN1767832A (zh) 2006-05-03
EP1620103A1 (en) 2006-02-01
GB0307860D0 (en) 2003-05-14
AU2004226825B2 (en) 2007-08-16
US20060194766A1 (en) 2006-08-31
JP2006522062A (ja) 2006-09-28
CA2521274A1 (en) 2004-10-14
WO2004087161A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
MY127290A (en) New use of flibanserin
EP1558220A4 (en) ORAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
WO2005002515A3 (en) Delivery of therapeutic compounds to the brain and other tissues
MY125821A (en) Pharmaceutical composition of topiramate
WO2008128740A8 (en) Titration of tapentadol
WO2005007111A3 (en) Tetrahydroquinoline derivatives as cannabinoid receptor modulators
SE0303571D0 (sv) Medical product for moisture-sensitive medicaments
WO2004043341A3 (en) Treatment for hemorrhagic shock
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
WO2004087880A3 (en) Compounds and their use to treat diabetes and related disorders
IL157226A0 (en) Composition and method for potentiating drugs
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
WO2005004854A3 (fr) Utilisation de la betaine pour le traitement des arterites
UA89753C2 (ru) Применение модафинила и антидепрессанта при лечении депрессии и для сокращения времени до начала действия антидепрессанта
BRPI0409170A (pt) combinações compreendendo drogas antiepilépticas para o tratamento de distúrbios neurológicos
WO2005092062A3 (en) Compounds for neurodegenerative disorders
IL168308A (en) Compositions containing roflumilast and formoterol
UA90504C2 (ru) Лекарственное средство для лечения заболеваний дыхательных путей
WO2005081972A3 (en) Maleiimide anti-tumor phosphatase inhibitors
MXPA05007253A (es) Sales novedosas de derivados anticonvulsivantes.
WO2005020904A3 (en) Oral neurotherapeutic cefazolin compositions
UA83017C2 (uk) Комбінація рофлуміласту та r,r-формотеролу для лікування захворювань дихальних шляхів
WO2008014232A3 (en) Pharmaceutical formulations for the treatment of alzheimer's disease
WO2005053709A3 (en) Pharmaceutical uses of bisphosphonates

Legal Events

Date Code Title Description
FA Abandonment or withdrawal